Large α-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 10, 2013, Pages 4087-4092

  Choi, Bong Kyu ^a   Choi, Mal Gi ^b   Kim, Jae Yeol ^a   Yang, Yoosoo ^b,c   Lai, Ying ^d   Kweon, Dae Hyuk ^c   Lee, Nam Ki ^a   Shin, Yeon Kyun ^b,d  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d IOWA STATE UNIVERSITY   (United States)

Author keywords

Alternating laser excitation; Exocytosis; Neuroscience; Single vesicle; Vesicle fusion

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; MONOMER; OLIGOMER; SNARE PROTEIN; SYNAPTOBREVIN 2;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; EXOCYTOSIS; LIPID VESICLE; MOLECULAR DOCKING; NERVE CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION;

ALPHA-SYNUCLEIN; ANIMALS; EXOCYTOSIS; LIPID METABOLISM; MODELS, NEUROLOGICAL; NEURONS; NEUROTOXINS; PC12 CELLS; PROTEIN BINDING; PROTEIN STRUCTURE, QUATERNARY; PROTEOLIPIDS; RATS; RECOMBINANT FUSION PROTEINS; SECRETORY VESICLES; SNARE PROTEINS; TRANSDUCTION, GENETIC; VESICLE-ASSOCIATED MEMBRANE PROTEIN 2;

EID: 84874611934     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1218424110     Document Type: Article

References (54)

1. Iwai A, et al. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14(2): 467-475.
2. Clayton DF, George JM (1998) The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci 21(6):249-254.
3. Spillantini MG, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839-840.
4. Irizarry MC, et al. (1998) Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 57(4):334-337.
5. Polymeropoulos MH, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047.
6. Zarranz JJ, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164-173.
7. Krüger R, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18(2):106-108.
8. Singleton AB, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302(5646):841.
9. Chartier-Harlin MC, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364(9440):1167-1169.
10. Bucciantini M, et al. (2002) Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416(6880):507-511.
11. Lotharius J, Brundin P (2002) Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 3(12):932-942.
12. Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 334(6180):345-348.
13. Halliday GM, et al. (1996) Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease. J Clin Neurosci 3(1):52-60.
14. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 114(Pt 5):2283-2301.
15. Venda LL, Cragg SJ, Buchman VL, Wade-Martins R (2010) α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci 33(12):559-568.
16. Mosharov EV, et al. (2009) Interplay between cytosolic dopamine, calcium, and alphasynuclein causes selective death of substantia nigra neurons. Neuron 62(2):218-229.
17. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294 (5545):1346-1349.
18. Cappai R, et al. (2005) Dopamine promotes alpha-synuclein aggregation into SDSresistant soluble oligomers via a distinct folding pathway. FASEB J 19(10):1377-1379.
19. Rekas A, et al. (2010) The structure of dopamine induced alpha-synuclein oligomers. Eur Biophys J 39(10):1407-1419.
20. Mazzulli JR, et al. (2006) Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26(39):10068-10078.
21. Yamakawa K, et al. (2010) Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun 391(1):129-134.
22. Martinez-Vicente M, et al. (2008) Dopamine-modified alpha-synuclein blocks chaperone- mediated autophagy. J Clin Invest 118(2):777-788.
23. Cooper AA, et al. (2006) Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313(5785):324-328.
24. Cabin DE, et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22(20):8797-8807.
25. Burré J, et al. (2010) Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329(5999):1663-1667.
26. Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC (2005) Alphasynuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123(3): 383-396.
27. Larsen KE, et al. (2006) Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J Neurosci 26(46):11915-11922.
28. Gitler AD, et al. (2008) The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci USA 105(1):145-150.
29. Nemani VM, et al. (2010) Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65(1):66-79.
30. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20(9):3214-3220.
31. Yavich L, Tanila H, Vepsäläinen S, Jäkälä P (2004) Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 24(49):11165-11170.
32. Südhof TC, Rothman JE (2009) Membrane fusion: Grappling with SNARE and SM proteins. Science 323(5913):474-477.
33. Jahn R, Scheller RH (2006) SNAREs-engines for membrane fusion. Nat Rev Mol Cell Biol 7(9):631-643.
34. Weber T, et al. (1998) SNAREpins:Minimal machinery for membrane fusion. Cell 92(6): 759-772.
35. Diao J, et al. (2012) Synaptic proteins promote calcium-triggered fast transition from point contact to full fusion. eLife 1:e00109.
36. Kyoung M, et al. (2011) In vitro system capable of differentiating fast Ca2+-triggered content mixing from lipid exchange for mechanistic studies of neurotransmitter release. Proc Natl Acad Sci USA 108(29):E304-E313.
37. Kyoung M, Zhang Y, Diao J, Chu S, Brunger AT (2013) Studying calcium-triggered vesicle fusion in a single vesicle-vesicle content and lipid-mixing system. Nat Protoc 8(1):1-16.
38. Kim JY, et al. (2012) Solution single-vesicle assay reveals PIP2-mediated sequential actions of synaptotagmin-1 on SNAREs. EMBO J 31(9):2144-2155.
39. Davidson WS, Jonas A, Clayton DF, George JM (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem 273(16):9443-9449.
40. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE (2000) alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem 275(44):34328-34334.
41. Eliezer D, Kutluay E, Bussell R Jr., Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307(4):1061-1073.
42. Volles MJ, et al. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40(26):7812-7819.
43. Volles MJ, Lansbury PT Jr (2002) Vesicle permeabilization by protofibrillar alphasynuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry 41(14):4595-4602.
44. Sudhof TC (2004) The synaptic vesicle cycle. Annu Rev Neurosci 27:509-547.
45. Jiang J, et al. (2004) Arachidonic acid-induced carbon-centered radicals and phospholipid peroxidation in cyclo-oxygenase-2-transfected PC12 cells. J Neurochem 90(5):1036-1049.
46. de Wit H, et al. (2009) Synaptotagmin-1 docks secretory vesicles to syntaxin-1/SNAP-25 acceptor complexes. Cell 138(5):935-946.
47. Gerber SH, et al. (2008) Conformational switch of syntaxin-1 controls synaptic vesicle fusion. Science 321(5895):1507-1510.
48. Li JY, Henning Jensen P, Dahlström A (2002) Differential localization of alpha-, betaand gamma-synucleins in the rat CNS. Neuroscience 113(2):463-478.
49. Andringa G, Du F, Chase TN, Bennett MC (2003) Mapping of rat brain using the Synuclein-1 monoclonal antibody reveals somatodendritic expression of alphasynuclein in populations of neurons homologous to those vulnerable to Lewy body formation in human synucleopathies. J Neuropathol Exp Neurol 62(10):1060-1075.
50. Kastner A, et al. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 59(3):1080-1089.
51. Halliday GM, et al. (2005) Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain 128(Pt 11):2654-2664.
52. Fasano M, Giraudo S, Coha S, Bergamasco B, Lopiano L (2003) Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein. Neurochem Int 42(7):603-606.
53. Kim C, Kim JY, Kim SH, Lee BI, Lee NK (2012) Direct characterization of protein oligomers and their quaternary structures by single-molecule FRET. Chem Commun (Camb) 48(8):1138-1140.
54. Ray P, Berman JD, Middleton W, Brendle J (1993) Botulinum toxin inhibits arachidonic acid release associated with acetylcholine release from PC12 cells. J Biol Chem 268(15): 11057-11064.